Department of Molecular Biology & Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, 08544, USA.
Commun Biol. 2021 Feb 15;4(1):203. doi: 10.1038/s42003-021-01731-z.
We recently linked branched-chain amino acid transferase 1 (BCAT1) dysfunction with the movement disorder Parkinson's disease (PD), and found that RNAi-mediated knockdown of neuronal bcat-1 in C. elegans causes abnormal spasm-like 'curling' behavior with age. Here we report the development of a machine learning-based workflow and its application to the discovery of potentially new therapeutics for PD. In addition to simplifying quantification and maintaining a low data overhead, our simple segment-train-quantify platform enables fully automated scoring of image stills upon training of a convolutional neural network. We have trained a highly reliable neural network for the detection and classification of worm postures in order to carry out high-throughput curling analysis without the need for user intervention or post-inspection. In a proof-of-concept screen of 50 FDA-approved drugs, enasidenib, ethosuximide, metformin, and nitisinone were identified as candidates for potential late-in-life intervention in PD. These findings point to the utility of our high-throughput platform for automated scoring of worm postures and in particular, the discovery of potential candidate treatments for PD.
我们最近将支链氨基酸转移酶 1 (BCAT1) 功能障碍与运动障碍帕金森病 (PD) 联系起来,并发现 RNAi 介导的秀丽隐杆线虫神经元 bcat-1 的敲低会导致随着年龄增长出现异常的痉挛样“卷曲”行为。在这里,我们报告了一种基于机器学习的工作流程的开发及其在发现 PD 潜在新疗法中的应用。除了简化定量和保持低数据开销外,我们简单的分段训练定量平台在训练卷积神经网络时能够对图像静止帧进行全自动评分。我们已经训练了一个高度可靠的神经网络来检测和分类蠕虫姿势,以便在无需用户干预或事后检查的情况下进行高通量卷曲分析。在对 50 种 FDA 批准药物的概念验证筛选中,依尼西坦、乙琥胺、二甲双胍和尼替西农被确定为 PD 潜在生命后期干预的候选药物。这些发现表明,我们的高通量平台非常适合自动评分蠕虫姿势,特别是发现 PD 的潜在候选治疗方法。